Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TRM003
MIFTS: 56

Tremor

Categories: Genetic diseases, Neuronal diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Tremor

About this section

MalaCards integrated aliases for Tremor:

Name: Tremor 55 30 6 44
Tremors 6

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Neuronal diseases Oral diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

ICD10 34 R25.1
Sources

Summaries for Tremor

About this section
NINDS : 55 Tremor is an unintentional, rhythmic, muscle movement involving to-and-fro movements of one or more parts of the body. Most tremors occur in the hands, although they can also affect the arms, head, face, voice, torso, and legs. Generally, tremor is caused by a problem in the deep parts of the brain that control movements.  Some forms of tremor are inherited and run in families, while others have no known cause. Sometimes tremor is a symptom of another neurological disorder or a side effect of certain drugs, but the most common form occurs in otherwise healthy people. Excessive alcohol consumption or alcohol withdrawal can kill certain nerve cells, resulting in tremor, especially in the hand. Other causes include an overactive thyroid and the use of certain drugs. Tremor may occur at any age but is most common in middle-aged and older adults. There are several types of tremor, one of the most common of which is essential tremor (sometimes called benign essential tremor). The hands are most often affected but the head, voice, tongue, legs, and trunk may also be involved. Head tremor may be seen as a "yes-yes" or "no-no" motion. Onset is most common after age 40, although symptoms can appear at any age. Parkinsonian tremor is caused by damage to structures within the brain that control movement. The tremor is classically seen as a "pill-rolling" action of the hands but may also affect the chin, face, lips, and legs. Dystonic tremor occurs in individuals of all ages who are affected by dystonia, a movement disorder which causes muscles to be over-active, resulting in abnormal postures or sustained, unwanted movements.

MalaCards based summary : Tremor, also known as tremors, is related to fragile x tremor/ataxia syndrome and fragile x-associated tremor/ataxia syndrome. An important gene associated with Tremor is C19orf12 (Chromosome 19 Open Reading Frame 12), and among its related pathways/superpathways are Neuroscience and Parkinsons Disease Pathway. The drugs Donepezil and Rotigotine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and testes, and related phenotypes are behavior/neurological and cardiovascular system

MedlinePlus : 44 Tremors are unintentional trembling or shaking movements in one or more parts of your body. Most tremors occur in the hands. You can also have arm, head, face, vocal cord, trunk, and leg tremors. Tremors are most common in middle-aged and older people, but anyone can have them. The cause of tremors is a problem in the parts of the brain that control muscles in the body or in specific parts of the body, such as the hands. They commonly occur in otherwise healthy people. They may also be caused by problems such as Parkinson's disease Dystonia Multiple sclerosis Stroke Traumatic brain injury Alcohol abuse and withdrawal Certain medicines Some forms are inherited and run in families. Others have no known cause. There is no cure for most tremors. Treatment to relieve them depends on their cause. In many cases, medicines and sometimes surgical procedures can reduce or stop tremors and improve muscle control. Tremors are not life-threatening. However, they can be embarrassing and make it hard to perform daily tasks. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 77 A tremor is an involuntary, somewhat rhythmic, muscle contraction and relaxation involving oscillations... more...

Sources

Related Diseases for Tremor

About this section

Diseases in the Tremor family:

Tremor, Hereditary Essential, 1 Tremor, Hereditary Essential, 2
Tremor, Hereditary Essential, 3 Tremor, Hereditary Essential, 4
Tremor, Hereditary Essential, 5 Essential Tremor

Diseases related to Tremor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 491)
# Related Disease Score Top Affiliating Genes
1 fragile x tremor/ataxia syndrome 34.2 FMR1 LOC108684022
2 fragile x-associated tremor/ataxia syndrome 34.1 FMR1 LOC108684022
3 essential tremor 33.2 DNAJC13 DRD3 FMR1 FUS HTRA2 LRRK2
4 multiple system atrophy 1 32.0 LRRK2 MAPT PRKN SNCA
5 movement disease 31.4 DRD3 FMR1 GBA LRRK2 MAPT PRKN
6 parkinson disease 15, autosomal recessive early-onset 31.1 C19orf12 PRKN SNCA
7 parkinson disease 2, autosomal recessive juvenile 31.0 HTRA2 LRRK2 PRKN SNCA
8 parkinson disease, late-onset 30.7 CHCHD2 DNAJC13 DRD3 GBA HTRA2 LRRK2
9 dementia 30.1 FUS GBA LRRK2 MAPT PRKN SNCA
10 supranuclear palsy, progressive, 1 30.0 LRRK2 MAPT PRKN SNCA
11 postencephalitic parkinson disease 29.6 LRRK2 MAPT SNCA
12 rem sleep behavior disorder 29.5 LRRK2 SNCA
13 neuronal intranuclear inclusion disease 29.5 MAPT SNCA
14 early-onset parkinson's disease 29.5 GBA LRRK2 PRKN SNCA
15 motor neuron disease 29.4 FUS MAPT SNCA
16 primary orthostatic tremor 12.5
17 tremor, hereditary essential, 1 12.4
18 tremor, hereditary essential, 4 12.4
19 tremor, hereditary essential, 5 12.3
20 tremor, hereditary essential, 2 12.2
21 tremor, nystagmus, and duodenal ulcer 12.1
22 tremor, hereditary essential, 3 12.1
23 tremor, hereditary essential, and idiopathic normal pressure hydrocephalus 12.0
24 tremor of intention, ataxia, and lipofuscinosis 12.0
25 sensorineural hearing loss-early graying-essential tremor syndrome 12.0
26 leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism 11.9
27 epilepsy, familial adult myoclonic, 5 11.8
28 epilepsy, familial adult myoclonic, 1 11.7
29 epilepsy, familial adult myoclonic, 2 11.7
30 epilepsy, familial adult myoclonic, 6 11.7
31 epilepsy, familial adult myoclonic, 7 11.7
32 mental retardation, x-linked, syndromic, cabezas type 11.6
33 myoclonic cerebellar dyssynergia 11.5
34 mental retardation, autosomal recessive 48 11.5
35 hereditary geniospasm 11.5
36 psychogenic movement 11.4
37 dystonia 11.4
38 hypertrophic olivary degeneration 11.3
39 multiple sclerosis 11.3
40 spinal and bulbar muscular atrophy, x-linked 1 11.3
41 cerebellar degeneration 11.2
42 focal dystonia 11.2
43 central pontine myelinolysis 11.2
44 roussy-levy hereditary areflexic dystasia 11.2
45 japanese encephalitis 11.2
46 spinocerebellar ataxia 6 11.2
47 spinocerebellar ataxia 2 11.2
48 wilson disease 11.2
49 hyperthyroidism 11.2
50 cervical dystonia 11.2

Graphical network of the top 20 diseases related to Tremor:



Diseases related to Tremor
Sources

Symptoms & Phenotypes for Tremor

About this section

MGI Mouse Phenotypes related to Tremor:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 CNTN2 CUL4B DRD3 FMR1 GBA HTRA2
2 cardiovascular system MP:0005385 9.96 CUL4B DRD3 GBA HTRA2 LRRK2 MAPT
3 cellular MP:0005384 9.9 CUL4B FMR1 GBA HTRA2 LRRK2 MAPT
4 integument MP:0010771 9.56 CUL4B FMR1 GBA HTRA2 LRRK2 MAPT
5 nervous system MP:0003631 9.44 CNTN2 CUL4B DRD3 FMR1 GBA HTRA2
Sources

Drugs & Therapeutics for Tremor

About this section

Drugs for Tremor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 553)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 4 120014-06-4 3152
2
Rotigotine Approved Phase 4,Phase 2 99755-59-6, 92206-54-7 57537
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
4
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
5
Carbetocin Approved, Investigational Phase 4 37025-55-1 71715 16681432
6
Oxytocin Approved, Vet_approved Phase 4,Phase 2 50-56-6 439302 53477758
7
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
8
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 525-66-6 4946
9
Gabapentin Approved, Investigational Phase 4,Phase 3,Not Applicable 60142-96-3 3446
10
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 137-58-6 3676
11
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113775-47-6 68602 5311068
12
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
13
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
14
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 22916-47-8 4189
15
Memantine Approved, Investigational Phase 4,Not Applicable 19982-08-2 4054
16
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2,Phase 1 148553-50-8 5486971
17
Levodopa Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59-92-7 6047
18
Entacapone Approved, Investigational Phase 4,Phase 3 130929-57-6 5281081
19
Carbidopa Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28860-95-9 34359
20
Glimepiride Approved Phase 4,Phase 3 93479-97-1 3476
21
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
22
Gliclazide Approved Phase 4,Phase 3 21187-98-4 3475
23
Glyburide Approved Phase 4,Phase 3 10238-21-8 3488
24
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-03-3
25
Procaterol Approved, Investigational Phase 4 72332-33-3 688561
26
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-23-7 5754
27
Pramipexole Approved, Investigational Phase 4,Phase 3 104632-26-0 119570 59868
28
Methadone Approved Phase 4,Phase 3,Phase 1 76-99-3 4095
29
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
30
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 93-14-1 3516
31
Ropinirole Approved, Investigational Phase 4,Phase 3 91374-21-9, 91374-20-8 5095 497540
32
Fluticasone Approved, Experimental Phase 4,Phase 3 90566-53-3 62924
33
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
34
Rasagiline Approved Phase 4,Phase 3,Phase 2 136236-51-6 3052776
35
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
36
Vancomycin Approved Phase 4,Phase 3 1404-90-6 441141 14969
37
Daptomycin Approved, Investigational Phase 4,Phase 3 103060-53-3 16129629
38
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 32051
39
Insulin Lispro Approved Phase 4 133107-64-9
40
Insulin glargine Approved Phase 4,Phase 2 160337-95-1
41
Terbutaline Approved Phase 4 23031-25-6 5403
42
Trimethobenzamide Approved, Investigational Phase 4 138-56-7 5577
43
Apomorphine Approved, Investigational Phase 4 41372-20-7, 58-00-4 6005
44
Topiramate Approved Phase 4,Phase 3 97240-79-4 5284627
45
Phentermine Approved, Illicit Phase 4,Not Applicable 122-09-8 4771
46
Levetiracetam Approved, Investigational Phase 4,Phase 1,Phase 2 102767-28-2 441341
47
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
48
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
49
Paroxetine Approved, Investigational Phase 4,Phase 3 61869-08-7 43815
50
Sertraline Approved Phase 4,Not Applicable 79617-96-2 68617

Interventional clinical trials:

(show top 50) (show all 811)
# Name Status NCT ID Phase Drugs
1 A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control Unknown status NCT00385359 Phase 4 Albuterol
2 The Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4 Donepezil
3 Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors Unknown status NCT03098368 Phase 4 Rotigotine;Placebo
4 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
5 The Role of Levothyroxine on Goiter With Atypia of Undetermined Significance Unknown status NCT02329379 Phase 4 Levothyroxine
6 Rapid Onset Action of Salbutamol Versus Formoterol Unknown status NCT00900874 Phase 4 salbutamol;Formoterol
7 The Effect of "Eye Drop Guide" on the Success Rate of Eye Drops Self-instillation in Glaucoma Patients Unknown status NCT01704248 Phase 4
8 ED90 Determination of Carbetocin for the Prevention of Uterine Atony in Women Undergoing an Elective Cesarean Delivery Unknown status NCT01579201 Phase 4 Carbetocin
9 Ultrasound Guided Pectoral Nerve I and II Blocks in Multimodal Analgesia for Breast Surgery Unknown status NCT02672813 Phase 4
10 A Pilot Clinical Trial Of Memantine for Essential Tremor Completed NCT00439699 Phase 4 Memantine
11 Pregabalin (Lyrica) for the Treatment of Essential Tremor Completed NCT00584376 Phase 4 Pregabalin;Placebo
12 Propranolol and Botulinum Toxin for Essential Vocal Tremor Completed NCT02111369 Phase 4 Propranolol
13 Pregabalin in the Treatment of Essential Tremor Completed NCT00646451 Phase 4 pregabalin;placebo capsules
14 Treatment of Pendular Nystagmus in OPT Completed NCT02466191 Phase 4 Memantine;Gabapentin
15 RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR) Completed NCT00998660 Phase 4
16 Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease Completed NCT00219284 Phase 4 Carbidopa/levodopa/entacapone
17 Effects of a Nutritional Supplement Combination on Body Weight Management Completed NCT01725958 Phase 4
18 Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease Completed NCT00646204 Phase 4 Memantine;placebo
19 Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263) Completed NCT01131182 Phase 4 Sitagliptin phosphate;Comparator: Sulfonylurea;Metformin
20 Aerosolized Beta-Agonist Isomers in Asthma Completed NCT02170532 Phase 4 levalbuterol;saline;ipratroprium
21 A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms Completed NCT00382967 Phase 4
22 Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management Completed NCT03103919 Phase 4 Rotigotine
23 Comparative Study on the Efficacy and Safety of Procaterol Versus Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room Completed NCT01091337 Phase 4 Procaterol;Salbutamol
24 Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms Completed NCT00297778 Phase 4 Pramipexole
25 QUALITY OF RECOVERY AFTER INTRAOPERATIVE MORPHINE OR METHADONE Completed NCT03045133 Phase 4 Methadone;Morphine
26 Multimodal Analgesic Technique for Control of Post-laproscopy Abdominal Pain Completed NCT03241602 Phase 4 Intraperitoneal lidocaine
27 A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease Completed NCT01494532 Phase 4 ropinirole/L-dopa;placebo/L-dopa
28 Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea Completed NCT00572975 Phase 4
29 Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler Completed NCT02416180 Phase 4
30 A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia Completed NCT00950664 Phase 4 Dysport® (abobotulinumtoxinA);Botox® (onabotulinumtoxinA)
31 Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity Measured Through Implanted Stimulators Completed NCT02256319 Phase 4 Dexmedetomidine;Propofol
32 The Effects of Formula Diet on Body Weight, Body Composition, and Biomarkers for Disease Compared to a Standard Diet Completed NCT00138645 Phase 4
33 Nebulized 3% Hypertonic Saline Solution Treatment of Bronchiolitis in Infants Completed NCT02233985 Phase 4 0.9% Sodium Chloride;3% Sodium Chloride
34 Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia Completed NCT00208091 Phase 4 Botulinum toxin, type B
35 Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease Completed NCT01723228 Phase 4 Rasagiline;Placebo
36 Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005) Completed NCT01728376 Phase 4 Daptomycin;Comparator
37 Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes Completed NCT00191282 Phase 4 Insulin lispro;Human insulin isophane suspension (NPH);Insulin glargine;Human insulin isophane suspension;Human insulin 30/70
38 Effects and Safety of Different Dose of Bambuterol on Chinese COPD Patients Completed NCT01796730 Phase 4 bambuterol;Placebo
39 Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment Completed NCT00489255 Phase 4 Tigan®;Placebo
40 A Toolbox Approach to Obesity Treatment in Primary Care Completed NCT01922934 Phase 4 Obesity pharmacotherapy
41 Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact Completed NCT00141518 Phase 4 Levodopa-carbidopa intestinal gel (LCIG)
42 Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients Completed NCT01523301 Phase 4 Rotigotine;Placebo
43 A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00206102 Phase 4 quetiapine fumarate;risperidone
44 An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00992407 Phase 4 Risperidone long acting injectables;Risperidone tablets
45 Antipsychotic Discontinuation in Alzheimer's Disease Completed NCT00417482 Phase 4 risperidone
46 An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment Completed NCT00526877 Phase 4 Risperidone
47 Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs Completed NCT00438451 Phase 4 Levetiracetam;Carbamazepine;Lamotrigine
48 A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder Completed NCT00677352 Phase 4 sertraline;Paroxetine
49 A Cross Over Pilot Study of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor Recruiting NCT03136341 Phase 4 Abobotulinum toxin A
50 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus

Search NIH Clinical Center for Tremor

Sources

Genetic Tests for Tremor

About this section

Genetic tests related to Tremor:

# Genetic test Affiliating Genes
1 Tremor 30
Sources

Anatomical Context for Tremor

About this section

MalaCards organs/tissues related to Tremor:

42
Brain, Eye, Testes, Thalamus, Tongue, Cerebellum, Subthalamic Nucleus
Sources

Publications for Tremor

About this section

Articles related to Tremor:

(show top 50) (show all 4283)
# Title Authors Year
1
The Roles of Age and Aging in Essential Tremor: An Epidemiological Perspective. ( 30625472 )
2019
2
Essential Tremor is not Only a Movement Disorder; Its Relationship with Sleep and Anxiety. ( 30911232 )
2019
3
A juvenile sporadic amyotrophic lateral sclerosis case with P525L mutation in the FUS gene: A rare co-occurrence of autism spectrum disorder and tremor. ( 30684766 )
2019
4
Secondary Cervical Dystonia and Titubatory Head Tremor. ( 30838321 )
2019
5
Dementia in Essential Tremor: A Visual Record. ( 30867979 )
2019
6
Familial ataxia, tremor, and dementia in a polish family with a novel mutation in the CCDC88C gene. ( 30398676 )
2019
7
Interleaving Stimulation in Parkinson's Disease, Tremor, and Dystonia. ( 30654368 )
2019
8
The clinical characteristics and related factors of tremor in patients with epilepsy. ( 30807902 )
2019
9
Cortical dynamics within and between parietal and motor cortex in essential tremor. ( 30345712 )
2019
10
White matter differences between essential tremor and Parkinson disease. ( 30504432 )
2019
11
A Quantitative Study of Empty Baskets in Essential Tremor and Other Motor Neurodegenerative Diseases. ( 30590599 )
2019
12
Reclassifying essential tremor: Implications for the future of past research. ( 30653249 )
2019
13
From beta-blockers to Parkinson's disease in respect of essential tremor. ( 30653724 )
2019
14
Reply to: From beta-blockers to Parkinson's disease in respect of essential tremor. ( 30653730 )
2019
15
Essential tremor severity and anatomical changes in brain areas controlling movement sequencing. ( 30656186 )
2019
16
Repeat magnetic resonance imaging-guided focused ultrasound thalamotomy for recurrent essential tremor: case report and review of MRI findings. ( 30684946 )
2019
17
Phenotypic Variability of Essential Tremor Based on the Age at Onset. ( 30688180 )
2019
18
An Acute Randomized Controlled Trial of Noninvasive Peripheral Nerve Stimulation in Essential Tremor. ( 30701655 )
2019
19
Essential Tremor. ( 30704686 )
2019
20
Yoga led by a physical therapist for individuals with Essential Tremor: An explorative pilot study. ( 30712723 )
2019
21
Peripheral BDNF/TrkB protein expression is decreased in Parkinson's disease but not in Essential tremor. ( 30723034 )
2019
22
Four-year follow-up results of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor. ( 30759322 )
2019
23
Shorter pulse width reduces gait disturbances following deep brain stimulation for essential tremor. ( 30765417 )
2019
24
Feasibility of Staged Bilateral Radiofrequency Vim Thalamotomy for Bilateral Essential Tremor. ( 30771542 )
2019
25
Correlation between fractional anisotropy changes in the targeted ventral intermediate nucleus and clinical outcome after transcranial MR-guided focused ultrasound thalamotomy for essential tremor: results of a pilot study. ( 30771772 )
2019
26
Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in essential tremor. ( 30785244 )
2019
27
Long-term efficacy of deep brain stimulation for essential tremor: An observer-blinded study. ( 30787161 )
2019
28
Personalized Bilateral Upper Limb Essential Tremor Therapy with Botulinum Toxin Using Kinematics. ( 30791440 )
2019
29
Unilateral Thalamic Deep Brain Stimulation vs. Focused Ultrasound Thalamotomy for Essential Tremor. ( 30794976 )
2019
30
Combined Visualization of Nigrosome-1 and Neuromelanin in the Substantia Nigra Using 3T MRI for the Differential Diagnosis of Essential Tremor and de novo Parkinson's Disease. ( 30809189 )
2019
31
Adjustment Distress to Successful Deep Brain Stimulation for Essential Tremor: Unexpected Intrapsychic Conflict in Response to Symptom Control. ( 30827494 )
2019
32
Decoding voluntary movements and postural tremor based on thalamic LFPs as a basis for closed-loop stimulation for essential tremor. ( 30827864 )
2019
33
Gait worsening and the microlesion effect following deep brain stimulation for essential tremor. ( 30846538 )
2019
34
Cognitive safety after unilateral magnetic resonance-guided focused ultrasound thalamotomy for essential tremor. ( 30850471 )
2019
35
Enfeeblement in Essential Tremor: Development and Validation of a New Psychometric Measure. ( 30857453 )
2019
36
Microstructural changes of the dentato-rubro-thalamic tract after transcranial MR guided focused ultrasound ablation of the posteroventral VIM in essential tremor. ( 30865338 )
2019
37
An Unusual Case of Essential Tremor Deep Brain Stimulation: Where is the Lead? ( 30867977 )
2019
38
Eye movement abnormalities in essential tremor versus tremor dominant Parkinson's disease. ( 30875535 )
2019
39
Mind the gaps: What we don't know about cognitive impairment in essential tremor. ( 30876840 )
2019
40
Focused Ultrasound Thalamotomy for Essential Tremor in the Setting of a Ventricular Shunt: Technical Report. ( 30888021 )
2019
41
Abnormal hippocampal subfields are associated with cognitive impairment in Essential Tremor. ( 30888510 )
2019
42
Prevalence of Essential Tremor in the Faroe Islands: A Population-Based Study. ( 30889566 )
2019
43
Adapted Feeding Utensils for People With Parkinson's-Related or Essential Tremor. ( 30915973 )
2019
44
Low diagnostic accuracy of fragile X tremor/ataxia syndrome diagnostic criteria in late onset ataxia. ( 30735585 )
2019
45
FMRpolyG alters mitochondrial transcripts level and respiratory chain complex assembly in Fragile X associated tremor/ataxia syndrome [FXTAS]. ( 30771487 )
2019
46
Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS). ( 30900185 )
2019
47
Functional neuroplasticity in response to cerebello-thalamic injury underpins the clinical presentation of tremor in multiple sclerosis. ( 30907236 )
2019
48
Validation of a precision tremor measurement system for multiple sclerosis. ( 30243994 )
2019
49
Tongue tremor in neurofascin-155 IgG4 seropositive chronic inflammatory polyradiculoneuropathy. ( 30713112 )
2019
50
Holmes tremor caused by a natalizumab-related progressive multifocal leukoencephalopathy: a case report and brief review of the literature. ( 30825017 )
2019
Sources

Variations for Tremor

About this section

ClinVar genetic disease variations for Tremor:

6 (show all 23)
# Gene Variation Type Significance SNP ID Assembly Location
1 LOC101927919; NUS1; SLC35F1 NC_000006.12 deletion Pathogenic GRCh37 Chromosome 6, 117961791: 118280044
2 LOC101927919; NUS1; SLC35F1 NC_000006.12 deletion Pathogenic GRCh38 Chromosome 6, 117640628: 117958881
3 LOC101927919; NUS1 NC_000006.12 deletion Pathogenic GRCh37 Chromosome 6, 117971549: 118218720
4 LOC101927919; NUS1 NC_000006.12 deletion Pathogenic GRCh38 Chromosome 6, 117650386: 117897557
5 covers 24 genes, none of which curated to show dosage sensitivity NC_000006.11 deletion Pathogenic GRCh37 Chromosome 6, 116681080: 119775014
6 TMEM67 NM_153704.5(TMEM67): c.1321C> T (p.Arg441Cys) single nucleotide variant Pathogenic/Likely pathogenic rs752362727 GRCh38 Chromosome 8, 93786255: 93786255
7 TMEM67 NM_153704.5(TMEM67): c.1321C> T (p.Arg441Cys) single nucleotide variant Pathogenic/Likely pathogenic rs752362727 GRCh37 Chromosome 8, 94798483: 94798483
8 TMEM67 NM_153704.5(TMEM67): c.1843T> C (p.Cys615Arg) single nucleotide variant Pathogenic/Likely pathogenic rs201893408 GRCh37 Chromosome 8, 94808198: 94808198
9 TMEM67 NM_153704.5(TMEM67): c.1843T> C (p.Cys615Arg) single nucleotide variant Pathogenic/Likely pathogenic rs201893408 GRCh38 Chromosome 8, 93795970: 93795970
10 GBA NM_001005741.2(GBA): c.1093G> A (p.Glu365Lys) single nucleotide variant risk factor rs2230288 GRCh37 Chromosome 1, 155206167: 155206167
11 GBA NM_001005741.2(GBA): c.1093G> A (p.Glu365Lys) single nucleotide variant risk factor rs2230288 GRCh38 Chromosome 1, 155236376: 155236376
12 C19orf12 NM_001031726.3(C19orf12): c.205G> A (p.Gly69Arg) single nucleotide variant Pathogenic rs515726205 GRCh37 Chromosome 19, 30193873: 30193873
13 C19orf12 NM_001031726.3(C19orf12): c.205G> A (p.Gly69Arg) single nucleotide variant Pathogenic rs515726205 GRCh38 Chromosome 19, 29702966: 29702966
14 C19orf12 NM_001031726.3(C19orf12): c.424A> G (p.Lys142Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs146170087 GRCh37 Chromosome 19, 30193654: 30193654
15 C19orf12 NM_001031726.3(C19orf12): c.424A> G (p.Lys142Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs146170087 GRCh38 Chromosome 19, 29702747: 29702747
16 MPZ NM_000530.7(MPZ): c.699T> G (p.Ser233Arg) single nucleotide variant Likely pathogenic rs1057518839 GRCh38 Chromosome 1, 161305924: 161305924
17 MPZ NM_000530.7(MPZ): c.699T> G (p.Ser233Arg) single nucleotide variant Likely pathogenic rs1057518839 GRCh37 Chromosome 1, 161275714: 161275714
18 GLI2 NM_005270.4(GLI2): c.2644A> T (p.Thr882Ser) single nucleotide variant Uncertain significance rs1332140763 GRCh38 Chromosome 2, 120988558: 120988558
19 GLI2 NM_005270.4(GLI2): c.2644A> T (p.Thr882Ser) single nucleotide variant Uncertain significance rs1332140763 GRCh37 Chromosome 2, 121746134: 121746134
20 ADGRV1 NM_032119.3(ADGRV1): c.5188A> T (p.Ile1730Phe) single nucleotide variant Uncertain significance rs1554079046 GRCh38 Chromosome 5, 90675320: 90675320
21 ADGRV1 NM_032119.3(ADGRV1): c.5188A> T (p.Ile1730Phe) single nucleotide variant Uncertain significance rs1554079046 GRCh37 Chromosome 5, 89971137: 89971137
22 CACNA1H NM_021098.2(CACNA1H): c.6884C> T (p.Ser2295Phe) single nucleotide variant Uncertain significance rs772718469 GRCh37 Chromosome 16, 1270816: 1270816
23 CACNA1H NM_021098.2(CACNA1H): c.6884C> T (p.Ser2295Phe) single nucleotide variant Uncertain significance rs772718469 GRCh38 Chromosome 16, 1220816: 1220816

Copy number variations for Tremor from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 247217 9 129375646 129461836 Deletion FAM129B Tremor
2 247222 9 129375646 129461836 Deletion STXBP1 Tremor
Sources

Expression for Tremor

About this section
Search GEO for disease gene expression data for Tremor.
Sources

Pathways for Tremor

About this section

Pathways related to Tremor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
11.63 CNTN2 FMR1 LRRK2 MAPT PRKN SNCA
2
Parkinsons Disease Pathway 1
11.18 HTRA2 LRRK2 PRKN SNCA
Sources

GO Terms for Tremor

About this section

Cellular components related to Tremor according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.98 C19orf12 CHCHD2 HTRA2 LRRK2 MAPT PRKN
2 cell projection GO:0042995 9.88 DRD3 FMR1 LRRK2 MAPT TENM4 TMEM67
3 lysosome GO:0005764 9.83 GBA LRRK2 MPZ SNCA
4 dendritic spine GO:0043197 9.71 FMR1 FUS MAPT
5 perikaryon GO:0043204 9.69 FMR1 FUS LRRK2
6 presynapse GO:0098793 9.65 FMR1 PRKN SNCA
7 axon GO:0030424 9.65 CNTN2 FMR1 LRRK2 MAPT SNCA
8 postsynapse GO:0098794 9.63 FMR1 LRRK2 SNCA
9 mitochondrial intermembrane space GO:0005758 9.5 CHCHD2 HTRA2 SNCA
10 inclusion body GO:0016234 9.49 LRRK2 SNCA
11 growth cone GO:0030426 9.46 FMR1 LRRK2 MAPT SNCA
12 neuron projection GO:0043005 9.43 CNTN2 FMR1 LRRK2 MAPT PRKN TENM4
13 glial cell projection GO:0097386 9.37 FMR1 MAPT
14 neuronal cell body GO:0043025 9.1 CNTN2 FMR1 FUS LRRK2 MAPT SNCA

Biological processes related to Tremor according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 response to oxidative stress GO:0006979 9.83 C19orf12 LRRK2 PRKN
2 autophagy GO:0006914 9.81 C19orf12 DRD3 LRRK2 PRKN
3 cellular response to oxidative stress GO:0034599 9.78 HTRA2 LRRK2 SNCA
4 negative regulation of protein phosphorylation GO:0001933 9.77 LRRK2 PRKN SNCA
5 neuron projection development GO:0031175 9.76 CNTN2 CUL4B GBA MAPT
6 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.75 GBA LRRK2 PRKN
7 regulation of autophagy GO:0010506 9.74 LRRK2 MAPT PRKN
8 learning GO:0007612 9.72 CNTN2 DRD3 PRKN
9 adult locomotory behavior GO:0008344 9.7 HTRA2 PRKN SNCA
10 regulation of reactive oxygen species metabolic process GO:2000377 9.66 PRKN SNCA
11 behavioral response to cocaine GO:0048148 9.65 DRD3 SNCA
12 regulation of neuron death GO:1901214 9.65 LRRK2 SNCA
13 regulation of neuronal synaptic plasticity GO:0048168 9.64 CNTN2 SNCA
14 microglial cell activation GO:0001774 9.64 MAPT SNCA
15 cellular protein catabolic process GO:0044257 9.63 HTRA2 PRKN
16 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.63 LRRK2 PRKN
17 positive regulation of proteasomal protein catabolic process GO:1901800 9.62 FMR1 PRKN
18 cellular response to dopamine GO:1903351 9.62 LRRK2 PRKN
19 supramolecular fiber organization GO:0097435 9.61 MAPT SNCA
20 cellular response to manganese ion GO:0071287 9.59 LRRK2 PRKN
21 intracellular distribution of mitochondria GO:0048312 9.58 LRRK2 MAPT
22 regulation of dopamine secretion GO:0014059 9.58 DRD3 PRKN SNCA
23 regulation of mitochondrial fission GO:0090140 9.56 LRRK2 MAPT
24 protein localization to mitochondrion GO:0070585 9.54 LRRK2 PRKN
25 regulation of neurotransmitter secretion GO:0046928 9.54 FMR1 PRKN SNCA
26 synaptic transmission, dopaminergic GO:0001963 9.5 DRD3 PRKN SNCA
27 dopamine uptake involved in synaptic transmission GO:0051583 9.49 PRKN SNCA
28 positive regulation of dopamine receptor signaling pathway GO:0060161 9.48 DRD3 LRRK2
29 regulation of synaptic vesicle transport GO:1902803 9.43 LRRK2 PRKN
30 dopamine metabolic process GO:0042417 9.43 DRD3 PRKN SNCA
31 mitochondrion organization GO:0007005 9.35 CHCHD2 GBA HTRA2 LRRK2 PRKN
32 regulation of locomotion GO:0040012 9.33 DRD3 LRRK2 SNCA
33 negative regulation of neuron death GO:1901215 9.02 GBA HTRA2 LRRK2 PRKN SNCA

Molecular functions related to Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 actin binding GO:0003779 9.62 LRRK2 MAPT PRKN SNCA
2 microtubule binding GO:0008017 9.46 FMR1 LRRK2 MAPT SNCA
3 dynein complex binding GO:0070840 9.37 FMR1 SNCA
4 phospholipase binding GO:0043274 9.26 PRKN SNCA
5 identical protein binding GO:0042802 9.23 CNTN2 FMR1 FUS HTRA2 LRRK2 MAPT
6 tubulin binding GO:0015631 9.13 LRRK2 MAPT PRKN
Sources

Sources for Tremor

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....